Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Mar;40(3):659–664. doi: 10.1128/aac.40.3.659

Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography.

A J Fischman 1, E Livni 1, J W Babich 1, N M Alpert 1, A Bonab 1, S Chodosh 1, F McGovern 1, P Kamitsuka 1, Y Y Liu 1, R Cleeland 1, B L Prosser 1, J A Correia 1, R H Rubin 1
PMCID: PMC163176  PMID: 8851589

Abstract

The pharmacokinetics of fleroxacin, a new broad-spectrum fluoroquinolone, were measured by positron emission tomography (PET) with [18F]fleroxacin in five patients with acute bacterial exacerbations of chronic bronchitis and in five patients with symptomatic, complicated urinary tract infection. Two studies were performed with each patient, one within 24 h of the initiation and one within 24 h of the completion of a 7-day course of fleroxacin, 400 mg/day. For each study, the patient received an infusion of that day's therapeutic dose of fleroxacin (400 mg) supplemented with approximately 740 MBq of [18F]fleroxacin, and serial PET images and blood samples were collected for 6 to 8 h starting at the initiation of the infusion. Between studies, the drug was administered orally. In all infected tissues, there was rapid accumulation of radiolabeled drug, with stable levels achieved within 1 h after completion of the infusion. In kidneys, accumulation was greater in the presence of active infection (P < 0.01), while in lungs, accumulation was lower (P < 0.02). Infection of the lung or urinary tract had no effect on drug delivery to uninvolved tissues. Also, there was no difference between the results obtained at the beginning and the end of therapy. Overall, peak concentrations of drug many times the MIC at which 90% of the infecting organisms are inhibited (MIC90) were achieved in the kidneys (> 30 micrograms/g), prostate glands (> 11 micrograms/g), and lungs (> 14 micrograms/g). Plateau concentrations (2 to 8 h; given as mean micrograms per gram +/- standard error of the mean) of drug in kidneys (15.11 +/- 0.55), prostate glands (5.08 +/- 0.19), and lungs (5.75 +/- 0.22) were also well above the MIC90 for most relevant pathogens. All patients had a good therapeutic response to fleroxacin.

Full Text

The Full Text of this article is available as a PDF (446.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoyama H., Inoue M., Mitsuhashi S. In-vitro and in-vivo antibacterial activity of fleroxacin, a new fluorinated quinolone. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):99–114. doi: 10.1093/jac/22.supplement_d.99. [DOI] [PubMed] [Google Scholar]
  2. Appelbaum P. C., Spangler S. K., Tamarree T. Susceptibility of 310 nonfermentative gram-negative bacteria to aztreonam, carumonam, ciprofloxacin, ofloxacin and fleroxacin. Chemotherapy. 1988;34(1):40–45. doi: 10.1159/000238546. [DOI] [PubMed] [Google Scholar]
  3. Arakawa S., Takagi S., Matsumoto O., Kamidono S., Sengoku A., Hazama M., Yamazaki H., Hamami G., Okamoto Y., Tanaka H. [A study on the treatment duration of an antibacterial agent in complicated urinary tract infections. Utility and recurrence after 14-day treatment by fleroxacin]. Jpn J Antibiot. 1991 Jul;44(7):718–731. [PubMed] [Google Scholar]
  4. Baba S., Mori Y., Maruo T. Penetration of fleroxacin into maxillary sinus mucosa and palatine tonsil. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):195–197. doi: 10.1093/jac/22.supplement_d.195. [DOI] [PubMed] [Google Scholar]
  5. Bannerman T. L., Wadiak D. L., Kloos W. E. Susceptibility of Staphylococcus species and subspecies to fleroxacin. Antimicrob Agents Chemother. 1991 Oct;35(10):2135–2139. doi: 10.1128/aac.35.10.2135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Barrett M. S., Jones R. N., Erwin M. E., Johnson D. M., Briggs B. M. Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628. Diagn Microbiol Infect Dis. 1991 Sep-Oct;14(5):389–401. doi: 10.1016/0732-8893(91)90066-o. [DOI] [PubMed] [Google Scholar]
  7. Bauernfeind A., Eberlein E., Hörl G. Bactericidal kinetics of various dosages of fleroxacin simulated in bacterial cultures. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):81–89. doi: 10.1093/jac/22.supplement_d.81. [DOI] [PubMed] [Google Scholar]
  8. Beskid G., Siebelist J., McGarry C. M., Cleeland R., Chan K., Keith D. D. In vivo evaluation of a dual-action antibacterial, Ro 23-9424, compared to cefotaxime and fleroxacin. Chemotherapy. 1990;36(2):109–116. doi: 10.1159/000238756. [DOI] [PubMed] [Google Scholar]
  9. Bowie W. R., Willetts V., Megran D. W. Dose-ranging study of fleroxacin for treatment of uncomplicated Chlamydia trachomatis genital infections. Antimicrob Agents Chemother. 1989 Oct;33(10):1774–1777. doi: 10.1128/aac.33.10.1774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Bremner D. A., Dickie A. S., Singh K. P. In-vitro activity of fleroxacin compared with three other quinolones. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):19–23. doi: 10.1093/jac/22.supplement_d.19. [DOI] [PubMed] [Google Scholar]
  11. Carson R. E., Daube-Witherspoon M. E., Green M. V. A method for postinjection PET transmission measurements with a rotating source. J Nucl Med. 1988 Sep;29(9):1558–1567. [PubMed] [Google Scholar]
  12. Chodosh S. Efficacy of fleroxacin versus amoxicillin in acute exacerbations of chronic bronchitis. Am J Med. 1993 Mar 22;94(3A):131S–135S. [PubMed] [Google Scholar]
  13. Chodosh S. Treatment of acute exacerbations of chronic bronchitis: state of the art. Am J Med. 1991 Dec 30;91(6A):87S–92S. doi: 10.1016/0002-9343(91)90317-q. [DOI] [PubMed] [Google Scholar]
  14. FOWLER J. F., YOUNG A. E. The average density of healthy lung. Am J Roentgenol Radium Ther Nucl Med. 1959 Feb;81(2):312–315. [PubMed] [Google Scholar]
  15. Fischman A. J., Livni E., Babich J., Alpert N. M., Liu Y. Y., Thom E., Cleeland R., Prosser B. L., Callahan R. J., Correia J. A. Pharmacokinetics of 18F-labeled fleroxacin in rabbits with Escherichia coli infections, studied with positron emission tomography. Antimicrob Agents Chemother. 1992 Oct;36(10):2286–2292. doi: 10.1128/aac.36.10.2286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fischman A. J., Livni E., Babich J., Alpert N. M., Liu Y. Y., Thom E., Cleeland R., Prosser B. L., Correia J. A., Strauss H. W. Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. Antimicrob Agents Chemother. 1993 Oct;37(10):2144–2152. doi: 10.1128/aac.37.10.2144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gasser T. C., Graversen P. H., Madsen P. O. Fleroxacin (Ro 23-6240) distribution in canine prostatic tissue and fluids. Antimicrob Agents Chemother. 1987 Jul;31(7):1010–1013. doi: 10.1128/aac.31.7.1010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Georgopoulos A., Breyer S., Georgopoulos M., Mailer H., Graninger W. In-vitro activity of fleroxacin. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):25–29. doi: 10.1093/jac/22.supplement_d.25. [DOI] [PubMed] [Google Scholar]
  19. Griggs D. J., Wise R., Kirkpatrick B., Ashby J. P. The metabolism and pharmacokinetics of fleroxacin in healthy subjects. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):191–194. doi: 10.1093/jac/22.supplement_d.191. [DOI] [PubMed] [Google Scholar]
  20. Kees F., Naber K. G., Schumacher H., Grobecker H. Penetration of fleroxacin into prostatic secretion and prostatic adenoma tissue. Chemotherapy. 1988;34(6):437–443. doi: 10.1159/000238605. [DOI] [PubMed] [Google Scholar]
  21. Kosmidis J., Gargalianos P., Adamis G., Petropoulou D., Makris D. Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infection. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):219–221. doi: 10.1093/jac/22.supplement_d.219. [DOI] [PubMed] [Google Scholar]
  22. Kropec A., Daschner F. In vitro activity of fleroxacin and 14 other antimicrobials against slime- and non-slime-producing Staphylococcus epidermidis. Chemotherapy. 1989;35(5):351–354. doi: 10.1159/000238694. [DOI] [PubMed] [Google Scholar]
  23. Kropec A., Daschner F. In vitro activity of fleroxacin and 6 other antimicrobials against Acinetobacter anitratus. Chemotherapy. 1989;35(5):360–362. doi: 10.1159/000238696. [DOI] [PubMed] [Google Scholar]
  24. Kusajima H., Ishikawa N., Machida M., Uchida H., Irikura T. Pharmacokinetics of a new quinolone, AM-833, in mice, rats, rabbits, dogs, and monkeys. Antimicrob Agents Chemother. 1986 Aug;30(2):304–309. doi: 10.1128/aac.30.2.304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kusajima H., Ooie T., Kawahara F., Uchida H. High-performance liquid chromatographic determination of 6,8-difluoro-1-(2-fluoroethyl)-1,4- dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid and its metabolites in laboratory animals. J Chromatogr. 1986 Aug 22;381(1):137–148. doi: 10.1016/s0378-4347(00)83572-0. [DOI] [PubMed] [Google Scholar]
  26. Leibovitz E., Keren G., Shabtai M., Barzilai A., Rubinstein E. The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. J Antimicrob Chemother. 1989 Sep;24(3):375–385. doi: 10.1093/jac/24.3.375. [DOI] [PubMed] [Google Scholar]
  27. Livni E., Babich J., Alpert N. M., Liu Y. Y., Thom E., Cleeland R., Prosser B. L., Correia J. A., Strauss H. W., Rubin R. H. Synthesis and biodistribution of 18F-labeled fleroxacin. Nucl Med Biol. 1993 Jan;20(1):81–87. doi: 10.1016/0969-8051(93)90139-l. [DOI] [PubMed] [Google Scholar]
  28. MacDonald K. S., Cameron D. W., D'Costa L., Ndinya-Achola J. O., Plummer F. A., Ronald A. R. Evaluation of fleroxacin (RO 23-6240) as single-oral-dose therapy of culture-proven chancroid in Nairobi, Kenya. Antimicrob Agents Chemother. 1989 May;33(5):612–614. doi: 10.1128/aac.33.5.612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Machka K., Braveny I. Comparative in vitro activity of RO 23-6240 (fleroxacin), a new 4-quinolone derivative. Eur J Clin Microbiol. 1987 Aug;6(4):482–485. doi: 10.1007/BF02013116. [DOI] [PubMed] [Google Scholar]
  30. Møller B. R., Kaspersen P., Mamsen A., Korsager B., Quitzau K. Fleroxacin in the treatment of uncomplicated acute cystitis in women. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):215–218. doi: 10.1093/jac/22.supplement_d.215. [DOI] [PubMed] [Google Scholar]
  31. Nakashima M., Kanamaru M., Uematsu T., Takiguchi A., Mizuno A., Itaya T., Kawahara F., Ooie T., Saito S., Uchida H. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):133–144. doi: 10.1093/jac/22.supplement_d.133. [DOI] [PubMed] [Google Scholar]
  32. Niki Y., Watanabe M., Tasaka Y., Umeki S., Soejima R. Therapeutic effect of fleroxacin against experimental pneumonia in mice. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):129–131. doi: 10.1093/jac/22.supplement_d.129. [DOI] [PubMed] [Google Scholar]
  33. Panneton A. C., Bergeron M. G., LeBel M. Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. Antimicrob Agents Chemother. 1988 Oct;32(10):1515–1520. doi: 10.1128/aac.32.10.1515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Plourde P. J., D'Costa L. J., Agoki E., Ombette J., Ndinya-Achola J. O., Slaney L. A., Ronald A. R., Plummer F. A. A randomized, double-blind study of the efficacy of fleroxacin versus trimethoprim-sulfamethoxazole in men with culture-proven chancroid. J Infect Dis. 1992 May;165(5):949–952. doi: 10.1093/infdis/165.5.949. [DOI] [PubMed] [Google Scholar]
  35. Portmann R., Hansz C., Stiglmayer R., Weidekamm E. Fleroxacin concentrations in myometrium, ovary and fallopian tube. J Antimicrob Chemother. 1989 Apr;23(4):662–664. doi: 10.1093/jac/23.4.662. [DOI] [PubMed] [Google Scholar]
  36. Pust R. A., Ackenheil-Köppe H. R., Weidner W., Meier-Ewert H. Clinical efficacy and tolerance of fleroxacin in patients with urethritis caused by Chlamydia trachomatis. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):227–230. doi: 10.1093/jac/22.supplement_d.227. [DOI] [PubMed] [Google Scholar]
  37. Rota Kops E., Herzog H., Schmid A., Holte S., Feinendegen L. E. Performance characteristics of an eight-ring whole body PET scanner. J Comput Assist Tomogr. 1990 May-Jun;14(3):437–445. doi: 10.1097/00004728-199005000-00022. [DOI] [PubMed] [Google Scholar]
  38. Rubin R. H., Shapiro E. D., Andriole V. T., Davis R. J., Stamm W. E. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992 Nov;15 (Suppl 1):S216–S227. doi: 10.1093/clind/15.supplement_1.s216. [DOI] [PubMed] [Google Scholar]
  39. Saito I., Suzuki A., Yokozawa M., Ono K., Miyamura R., Hamaya O. [Bacteriological and clinical studies on fleroxacin in male gonococcal urethritis]. Hinyokika Kiyo. 1991 Jun;37(6):663–668. [PubMed] [Google Scholar]
  40. Sorgel F., Metz R., Naber K., Seelmann R., Muth P. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):155–167. doi: 10.1093/jac/22.supplement_d.155. [DOI] [PubMed] [Google Scholar]
  41. Stuck A. E., Kim D. K., Frey F. J. Fleroxacin clinical pharmacokinetics. Clin Pharmacokinet. 1992 Feb;22(2):116–131. doi: 10.2165/00003088-199222020-00003. [DOI] [PubMed] [Google Scholar]
  42. Weidekamm E., Portmann R., Suter K., Partos C., Dell D., Lücker P. W. Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. Antimicrob Agents Chemother. 1987 Dec;31(12):1909–1914. doi: 10.1128/aac.31.12.1909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Wise R., Honeybourne D., Andrews J. M., Ashby J. P. The penetration of fleroxacin into bronchial mucosa. J Antimicrob Chemother. 1988 Aug;22(2):203–206. doi: 10.1093/jac/22.2.203. [DOI] [PubMed] [Google Scholar]
  44. Wise R., Kirkpatrick B., Ashby J., Griggs D. J. Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone. Antimicrob Agents Chemother. 1987 Feb;31(2):161–163. doi: 10.1128/aac.31.2.161. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES